15 Jun 2024 • A recent study on patients with stroke (without thrombectomy) revealed that tenecteplase initiated within 4.5 to 24 hours of stroke symptoms greatly reduced the disability and mortality rates at 90 days.

In a trial in China, patients with large-vessel occlusion of the middle cerebral artery or internal carotid artery were randomly assigned to receive either tenecteplase or standard medical treatment. Tenecteplase was given within 4.5 to 24 hours after stroke onset. The primary outcome was the absence of disability at day 90.

The study found that treatment with tenecteplase resulted in a higher percentage of patients with no or minimal disability (33.0%) compared to standard medical treatment (24.2%) at 90 days. Their Modified Rankin scale scores were 0/1. Mortality rates and the incidence of symptomatic intracranial hemorrhage were similar between the two groups (13.3% vs. 13.1%).

Tenecteplase showed promise as a treatment option for ischemic stroke patients who did not undergo endovascular thrombectomy.

Source:NEJM| Read full story